Marta Correia de Sousa

TL;DR: The current knowledge on miRNA editing is discussed and how this mechanism regulates miRNA biogenesis and activity is discussed to deepen the knowledge of molecular mechanisms underlying complex diseases.

TL;DR: The potential therapeutic usages in a short to medium term of miRNA-based strategies in NAFLD, in particular to identify non-invasive biomarkers, or to design pharmacological analogues/inhibitors having a broad range of actions on hepatic metabolism, are highlighted.

TL;DR: It is observed that alterations of hepatic miR-22-3p expression with non-alcoholic fatty liver disease (NAFLD) in the context of obesity are not consistent in various human cohorts and animal models in contrast to the well-characterized miR+3p downregulation observed in hepatic cancers.

TL;DR: Current knowledge of the roles and functions of AUBPs in liver diseases and cancer is discussed and the relevance of AubPs as potential biomarkers for different stages of FLD and HCC, or as therapeutic targets for these diseases, are highlighted.

TL;DR: The microRNA 21 (miR-21) is upregulated in almost all known human cancers and is considered a highly potent oncogene and potential therapeutic target for cancer treatment.